ECTS2013 Oral Communications Treatment of osteoporosis (6 abstracts)
A Three-year randomized sham-controlled trial of low magnitude mechanical stimulation in an elderly sample: the ‘VIBES' trial
Douglas Kiel 1 , Marian Hannan 1 , Emily Sisson 2 , Mary Bouxsein 3 , Bruce Barton 4 , Dawn Dewkett 1 , Jay Magaziner 5 , Sheryl Zimmerman 6 , Elizabeth Shane 7 , Elizabeth Teng Leary 8 , Danette Carroll 1 , Brett Allaire 3 , Thomas Lang 9 & Clinton Rubin 10
1Harvard Medical School, Institute for Aging Research Hebrew Senior Life, Boston, Massachusetts, USA; 2Boston University School of Public Health Data Coordinating Center, Boston, Massachusetts, USA; 3Harvard Medical School, Center for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 4University of Massachusetts Medical School, Worcester, Massachusetts, USA; 5Division of Gerontology, Department of Epidemiology and Preventive Medicine, University of Maryland, Baltimore, Maryland, USA; 6Program on Aging, Disability and Long Term Care, Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina, USA; 7Columbia University College of Physicians and Surgeons, New York, New York, USA; 8Pacific Biomarkers, Seattle, Washington, USA; 9Department of Radiology, University of California, San Francisco, California, USA; 10Biomedical Engineering, SUNY, Stony Brook, New York, USA.
Non-pharmacologic approaches to preserve or increase BMD include whole body vibration (WBV). A meta-analysis and one-year randomized trial concluded that WBV has no effect on BMD in older women; however, previous trials were relatively brief and did not include a sham control group. Therefore, we conducted the Vibration to Improve Bone in Elderly Subjects (‘VIBES’) trial, a randomized, sham-controlled trial of 10 min of daily WBV (0.3 g at 30 Hz) in seniors recruited from 16 independent living communities around Boston Massachusetts, USA. We randomized 174 men and women (89 active, 85 sham) with T-scores −1 to −2.5 who were not taking bone active drugs and had no diseases affecting the skeleton (mean age 82±7 years, range 65–102). The trial was originally planned for 2 years, but was extended for a third year. Participants received calcium 1000 mg and vitamin D 800 IU. Shared intervention platforms were activated using radiofrequency ID cards providing electronic adherence monitoring. ‘Sham’ platforms resembled the active platforms. In total, 61% of participants in the active arm and 73% in the sham arm completed 24 months. Of 29 individuals assigned to the active arm who agreed to a third year, 97% completed it; for the sham arm, 85% of 26 completed the third year. The primary outcomes measured by QCT, absolute changes in total femoral trabecular BMD, and in average mid-vertebral trabecular BMD of L1 and L2, were no different between active and sham arms (differences=0.0011 and 0.0003 g/cm3 respectively, all P values >0.2). Changes in biochemical markers of bone turnover (P1NP and sCTX) did not differ between groups (P=0.18 and P=0.97 respectively). Overall, mean adherence was 69%. In conclusion, this sham-controlled randomized trial of daily WBV in seniors of advanced age did not demonstrate evidence of beneficial effects on QCT BMD.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more